MX2022008491A - Composicion farmaceutica que comprende empagliflozina y sus usos. - Google Patents

Composicion farmaceutica que comprende empagliflozina y sus usos.

Info

Publication number
MX2022008491A
MX2022008491A MX2022008491A MX2022008491A MX2022008491A MX 2022008491 A MX2022008491 A MX 2022008491A MX 2022008491 A MX2022008491 A MX 2022008491A MX 2022008491 A MX2022008491 A MX 2022008491A MX 2022008491 A MX2022008491 A MX 2022008491A
Authority
MX
Mexico
Prior art keywords
empagliflozin
pharmaceutical composition
heart failure
hospitalization
preserved
Prior art date
Application number
MX2022008491A
Other languages
English (en)
Inventor
Uli Broedl
Afshin Salsali
Hans- Juergen WOERLE
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2022008491A publication Critical patent/MX2022008491A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a métodos para prevenir o tratar insuficiencia cardíaca crónica o aguda y para reducir el riesgo de muerte cardiovascular, hospitalización por insuficiencia cardíaca y otras afecciones en pacientes con fracción de eyección reducida o conservada mediante la administración de empagliflozina al paciente.
MX2022008491A 2016-03-16 2018-09-13 Composicion farmaceutica que comprende empagliflozina y sus usos. MX2022008491A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309008P 2016-03-16 2016-03-16
US201662420062P 2016-11-10 2016-11-10

Publications (1)

Publication Number Publication Date
MX2022008491A true MX2022008491A (es) 2022-08-02

Family

ID=58267120

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2018011088A MX2018011088A (es) 2016-03-16 2017-03-13 Composicion farmaceutica que comprende empagliflozina y sus usos.
MX2022008491A MX2022008491A (es) 2016-03-16 2018-09-13 Composicion farmaceutica que comprende empagliflozina y sus usos.
MX2021010329A MX2021010329A (es) 2016-03-16 2018-09-13 Composicion farmaceutica que comprende empagliflozina y sus usos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018011088A MX2018011088A (es) 2016-03-16 2017-03-13 Composicion farmaceutica que comprende empagliflozina y sus usos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010329A MX2021010329A (es) 2016-03-16 2018-09-13 Composicion farmaceutica que comprende empagliflozina y sus usos.

Country Status (13)

Country Link
US (5) US20170266152A1 (es)
EP (1) EP3429595A1 (es)
JP (3) JP7161405B2 (es)
KR (4) KR20180122004A (es)
CN (1) CN109069525A (es)
AU (2) AU2017233889B2 (es)
BR (1) BR112018016001A2 (es)
CA (1) CA3017992A1 (es)
CL (1) CL2018002532A1 (es)
MA (1) MA43709A (es)
MX (3) MX2018011088A (es)
PH (1) PH12018501969A1 (es)
WO (1) WO2017157816A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
US10610489B2 (en) 2009-10-02 2020-04-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
AR085689A1 (es) 2011-03-07 2013-10-23 Boehringer Ingelheim Int Composiciones farmaceuticas de metformina, linagliptina y un inhibidor de sglt-2
HUE041709T2 (hu) 2013-04-05 2019-05-28 Boehringer Ingelheim Int Az empagliflozin terápiás alkalmazásai
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2906115T3 (es) 2013-04-18 2022-04-13 Boehringer Ingelheim Int Composición farmacéutica, métodos de tratamiento y usos de la misma
WO2019069230A1 (en) * 2017-10-02 2019-04-11 Poxel METHODS OF TREATING CARDIAC INSUFFICIENCY WITH PRESERVED EJECTION FRACTION
MX2020013567A (es) 2018-06-14 2021-05-27 Poxel Tableta recubierta con pelicula que comprende un derivado de triazina para su uso en el tratamiento de la diabetes.
KR20210034039A (ko) 2018-07-19 2021-03-29 아스트라제네카 아베 다파글리플로진을 사용하는 HFpEF의 치료 방법 및 이를 포함하는 조성물
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN109846898A (zh) * 2019-02-01 2019-06-07 同济大学 恩格列净在制备治疗和/或预防心肌梗死的药物中的应用
CN114286682A (zh) * 2019-02-09 2022-04-05 法码科思莫斯控股有限公司 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁
IT201900006624A1 (it) * 2019-05-08 2020-11-08 Moret Giannino Combinazione di canrenone e enalapril per uso nella terapia dei pazienti diabetici.
AU2020202887B2 (en) * 2019-08-30 2021-05-20 Astrazeneca Ab Methods of treating heart failure with reduced ejection fraction with dapagliflozin
JPWO2021049612A1 (es) * 2019-09-13 2021-03-18
CA3167531A1 (en) 2020-02-17 2021-08-26 Boehringer Ingelheim Vetmedica Gmbh Use of sglt-2 inhibitors for the prevention and/or treatment of cardiac diseases in felines
CN117715640A (zh) 2021-07-28 2024-03-15 勃林格殷格翰动物保健有限公司 Sglt-2抑制剂用于在不包括猫科动物的非人哺乳动物，特别是犬科动物中预防和/或治疗心脏疾病的用途
JP7396579B2 (ja) 2022-01-31 2023-12-12 壽製薬株式会社 左室駆出率が保たれた心不全に対する医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723309B2 (en) * 2005-05-03 2010-05-25 Boehringer Ingelheim International Gmbh Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments
UA91546C2 (uk) * 2005-05-03 2010-08-10 Бьорінгер Інгельхайм Інтернаціональ Гмбх КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
CL2008002427A1 (es) * 2007-08-16 2009-09-11 Boehringer Ingelheim Int Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
MX2012002942A (es) * 2009-09-30 2012-04-11 Boehringer Ingelheim Int Metodo para la preparacion de una forma cristalina de 1-cloro-4-(beta-d-glucopiranos-1-il)-2-(4-((s)-teteahidrofuran-3- iloxi)bencil)-benceno.
US20130035298A1 (en) * 2011-07-08 2013-02-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US9192617B2 (en) * 2012-03-20 2015-11-24 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US20140303097A1 (en) * 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CA2812016A1 (en) * 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
ES2906115T3 (es) * 2013-04-18 2022-04-13 Boehringer Ingelheim Int Composición farmacéutica, métodos de tratamiento y usos de la misma

Also Published As

Publication number Publication date
US20220211659A1 (en) 2022-07-07
KR20230028565A (ko) 2023-02-28
US20210059974A1 (en) 2021-03-04
US20180318251A1 (en) 2018-11-08
AU2017233889A1 (en) 2018-08-09
EP3429595A1 (en) 2019-01-23
CL2018002532A1 (es) 2019-01-04
MX2021010329A (es) 2021-10-13
CA3017992A1 (en) 2017-09-21
MA43709A (fr) 2018-11-28
JP2023001136A (ja) 2023-01-04
JP2019508453A (ja) 2019-03-28
KR20230028568A (ko) 2023-02-28
MX2018011088A (es) 2018-11-22
US20190350894A1 (en) 2019-11-21
BR112018016001A2 (pt) 2018-12-18
JP2021181461A (ja) 2021-11-25
AU2017233889B2 (en) 2022-07-07
KR20230111262A (ko) 2023-07-25
CN109069525A (zh) 2018-12-21
AU2022246392A1 (en) 2022-10-27
JP7161405B2 (ja) 2022-10-26
KR20180122004A (ko) 2018-11-09
US20170266152A1 (en) 2017-09-21
JP7454531B2 (ja) 2024-03-22
PH12018501969A1 (en) 2019-06-17
WO2017157816A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
PH12018501969A1 (en) Pharmaceutical composition comprising empagliflozin and uses thereof
PH12020500352A1 (en) Therapeutic uses of empagliflozin
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
PH12015502310B1 (en) Pharmaceutical composition, methods for treating and uses thereof
MX2018002990A (es) Uso de la akkermansia pasteurizada para tratar trastornos metabolicos.
MX2015013948A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
AU2014375637A1 (en) Formula of neuregulin preparation
BR112018003745A2 (pt) composições que compreendem um composto de urolitina
MX2018002546A (es) Composiciones que comprenden un compuesto de urolitina.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
PH12019501439A1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
MX2017003217A (es) Tratamiento del cancer con el inhibidor de la alfa-amilasa en los animales de compañía.
AU2017258649A1 (en) Covalent BTK inhibitors and uses thereof
MD4763B1 (ro) Compoziţie farmaceutică
WO2016191458A3 (en) Pharmaceutical compositions affecting mitochondrial redox state and methods of treatment
MX2023005014A (es) Metodos de tratamiento de enfermedades inflamatorias cronicas.
BR112017015840A2 (pt) método de tratamento ou prevenção de eventos aterotrombóticos em pacientes com histórico de infarto do miocárdio
EA201892048A1 (ru) Фармацевтическая композиция, содержащая эмпаглифлозин, и ее применения
WO2019078634A3 (ko) Ptp4a1 단백질을 포함하는 인슐린 저항성 또는 지방간의 예방 또는 치료용 약학적 조성물
MX2014010749A (es) Composicion ginecologica para tratar la vestibulitis vulvar.
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
WO2017010673A3 (ko) 혈관누수 증후군의 예방 또는 치료용 조성물
MX2017011838A (es) Composiciones y metodos para tratar carcinoma hepatocelular.
EA201991119A1 (ru) Фармацевтическая композиция, способы лечения и ее применения
WO2014075033A3 (en) Protein stabilizing factors